Cargando…
RF04 | PSUN295 Evolution of Monomeric Multi-Agonists of GLP-1 and NPY Receptors
Current treatments for type 2 diabetes (T2D) and obesity do not reliably achieve long-term weight-loss and up to 50% of patients experience nausea and vomiting. Thus, there is a critical need for obesity medications that provide glycemic control with enhanced hypophagic response without nausea/emesi...
Autores principales: | Chichura, Kylie, Elfers, Clinton, Salameh, Therese, Sweet, Ian, Roth, Christian, Doyle, Prof Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625289/ http://dx.doi.org/10.1210/jendso/bvac150.871 |
Ejemplares similares
-
RF04 | PSUN334 Mineralocorticoid receptors mediate diet - induced lipid infiltration of skeletal muscle and insulin resistance
por: Habibi, Javad, et al.
Publicado: (2022) -
RF04 | PSUN233 Design of an Ultra-Stable Insulin/Glucagon Fusion Protein
por: Grabowski, Rachel, et al.
Publicado: (2022) -
RF04 | PSUN135 Genetic Inactivation of Glutaminase Reduces Amino Acid Induced Alpha Cell Proliferation
por: Shou, Matthew, et al.
Publicado: (2022) -
RF28 | PSUN182 Risk of Pancreatitis After Glp-1 Receptor Agonist in Individuals With Known History of Pancreatitis
por: Kodali, Alimitha M, et al.
Publicado: (2022) -
RF04 | PSUN298 Loss of β-Cell Glut2 Does Not Affect Systemic Glucose Homeostasis in Mice
por: Bathina, Siresha, et al.
Publicado: (2022)